HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study.

AbstractBACKGROUND:
Gastrointestinal tract (GIT) dysfunction is common in Parkinson's disease (PD) patients. However, it remains unclear whether levodopa affects GIT function in PD.
OBJECTIVE:
To perform an open study of levodopa's effects on anorectal constipation in de novo PD patients by the quantitative lower-gastrointestinal autonomic test (QL-GAT).
METHODS:
Nineteen unselected de novo PD patients (10 men, 9 women; mean age, 66 years; mean duration of the disease, 2.2 years) were recruited for the study. Eighteen of the patients reported constipation. These patients were treated with 200/20 mg b.i.d. of levodopa/carbidopa for 3 months. Pre- and post-treatment, objective parameters in the QL-GAT that comprised the colonic transit time (CTT) and rectoanal videomanometry were obtained.
RESULTS:
Levodopa was well tolerated by all patients. There was a trend toward subjective improvements in bowel frequency and difficulty defecating. Levodopa did not significantly change CTT of the total colon or any segment of the colon. During rectal filling, levodopa significantly lessened the first sensation (p < 0.05). It also tended to augment the amplitude of spontaneous phasic rectal contraction (not statistically significant). During defecation, levodopa significantly lessened the amplitude in paradoxical sphincter contraction upon defecation (PSD) (p < 0.01). It also tended to augment the amplitude of rectal contraction and lessen the amplitude of abdominal strain (not statistically significant). Overall, levodopa significantly lessened post-defecation residuals (p < 0.05).
CONCLUSIONS:
The QL-GAT in the present study showed for the first time that levodopa augmented rectal contraction, lessened PSD, and thereby ameliorated anorectal constipation in de novo PD patients.
AuthorsFuyuki Tateno, Ryuji Sakakibara, Yuko Yokoi, Masahiko Kishi, Emina Ogawa, Tomoyuki Uchiyama, Tatsuya Yamamoto, Tomonori Yamanishi, Osamu Takahashi
JournalParkinsonism & related disorders (Parkinsonism Relat Disord) Vol. 17 Issue 9 Pg. 662-6 (Nov 2011) ISSN: 1873-5126 [Electronic] England
PMID21705259 (Publication Type: Clinical Trial, Journal Article)
CopyrightCopyright © 2011 Elsevier Ltd. All rights reserved.
Chemical References
  • Antiparkinson Agents
  • Levodopa
  • Carbidopa
Topics
  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents (therapeutic use)
  • Carbidopa (therapeutic use)
  • Constipation (drug therapy, etiology)
  • Female
  • Humans
  • Levodopa (therapeutic use)
  • Male
  • Middle Aged
  • Parkinson Disease (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: